InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
Epistemonikos ID: a832c77e36429660e9b1b2957e0b282309b32006
First added on: May 09, 2020